Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 223

Similar articles for PubMed (Select 6271844)

1.

Nabilone: an effective antiemetic in patients receiving cancer chemotherapy.

Einhorn LH, Nagy C, Furnas B, Williams SD.

J Clin Pharmacol. 1981 Aug-Sep;21(8-9 Suppl):64S-69S.

PMID:
6271844
3.

Evolving treatment paradigms for chemotherapy-induced nausea and vomiting.

Wickham R.

Cancer Control. 2012 Apr;19(2 Suppl):3-9. Review.

4.

Nabilone in inflammatory pain: to be or not to be.

Guindon J.

Clin Exp Pharmacol Physiol. 2012 Apr;39(4):327-8. doi: 10.1111/j.1440-1681.2012.05687.x. No abstract available.

PMID:
22449419
5.

The abuse potential of the synthetic cannabinoid nabilone.

Ware MA, St Arnaud-Trempe E.

Addiction. 2010 Mar;105(3):494-503. doi: 10.1111/j.1360-0443.2009.02776.x. Review.

PMID:
20402993
6.

Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.

Grunberg SM, Dugan M, Muss H, Wood M, Burdette-Radoux S, Weisberg T, Siebel M.

Support Care Cancer. 2009 May;17(5):589-94. doi: 10.1007/s00520-008-0535-9. Epub 2008 Nov 27.

PMID:
19037667
7.

A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting.

Ware MA, Daeninck P, Maida V.

Ther Clin Risk Manag. 2008 Feb;4(1):99-107.

8.

A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.

Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W, Koh J, Yeung WK, Kwan WH, Lee KK, Mok TS, Poon AN, Lam KC, Hui EK, Zee B.

Breast Cancer Res Treat. 2009 Feb;113(3):529-35. doi: 10.1007/s10549-008-9957-9. Epub 2008 Mar 10.

PMID:
18327706
9.

Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain.

Davis MP.

Expert Opin Investig Drugs. 2008 Jan;17(1):85-95. Review.

PMID:
18095921
10.

Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.

Pradermdee P, Manusirivithaya S, Tangjitgamol S, Thavaramara T, Sukwattana P.

J Med Assoc Thai. 2006 Oct;89 Suppl 4:S29-36.

PMID:
17725140
11.

Efficacy of aprepitant in management of chemotherapy-induced nausea and vomiting.

Osorio-Sanchez JA, Karapetis C, Koczwara B.

Intern Med J. 2007 Apr;37(4):247-50.

PMID:
17388865
12.

A double-blind, crossover, randomized dose-comparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy.

Berrak SG, Ozdemir N, Bakirci N, Turkkan E, Canpolat C, Beker B, Yoruk A.

Support Care Cancer. 2007 Oct;15(10):1163-8. Epub 2007 Mar 20.

PMID:
17372773
13.

The emerging role of cannabinoid neuromodulators in symptom management.

Davis M, Maida V, Daeninck P, Pergolizzi J.

Support Care Cancer. 2007 Jan;15(1):63-71. Epub 2006 Dec 1. Review.

PMID:
17139494
14.

Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy.

Herrstedt J, Sigsgaard TC, Nielsen HA, Handberg J, Langer SW, Ottesen S, Dombernowsky P.

Support Care Cancer. 2007 Apr;15(4):417-26. Epub 2006 Nov 9.

PMID:
17093916
15.

Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.

Lindley C, Goodin S, McCune J, Kane M, Amamoo MA, Shord S, Pham T, Yowell S, Laliberte K, Schell M, Bernard S, Socinski MA.

Am J Clin Oncol. 2005 Jun;28(3):270-6.

PMID:
15923800
16.

Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.

Herrstedt J.

Expert Opin Drug Saf. 2004 May;3(3):231-48. Review.

PMID:
15155151
17.

The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers.

Ihbe-Heffinger A, Ehlken B, Bernard R, Berger K, Peschel C, Eichler HG, Deuson R, Thödtmann J, Lordick F.

Ann Oncol. 2004 Mar;15(3):526-36.

19.

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.

Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ; Aprepitant Protocol 052 Study Group.

J Clin Oncol. 2003 Nov 15;21(22):4112-9. Epub 2003 Oct 14.

PMID:
14559886
20.

A CONTROLLED CLINICAL EVALUATION OF ANTIEMETIC DRUGS.

MOERTEL CG, REITEMEIER RJ, GAGE RP.

JAMA. 1963 Oct 12;186:116-8. No abstract available.

PMID:
14056524
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk